0
0
9/12/23 at 6:57pm
Organization
Contemporarypediatrics.com
41 words
0
Comments
A supplemental biologics license application for ALTUVIIIO (Antihemophilic factor; Sanofi) has been accepted by the FDA for use in patients aged 12 years and older with severe hemophilia A.
You are the first to view
https://www.contemporarypediatrics.com/view/fda-accepts-slba-for-altuviiio-in-children-with-hemophilia-a
Create an account
or login to join the discussion